Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.
3.
5.

Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.

Tornos C, Soslow R, Chen S, Akram M, Hummer AJ, Abu-Rustum N, Norton L, Tan LK.

Am J Surg Pathol. 2005 Nov;29(11):1482-9. Erratum in: Am J Surg Pathol. 2006 Jan;30(1):140.

PMID:
16224215
6.

Metastatic adenocarcinoma to the brain: an immunohistochemical approach.

Perry A, Parisi JE, Kurtin PJ.

Hum Pathol. 1997 Aug;28(8):938-43.

PMID:
9269830
7.
8.

Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites.

Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P, Dietel M.

Histopathology. 1996 Sep;29(3):233-40.

PMID:
8884351
9.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
10.
12.

GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.

Shield PW, Papadimos DJ, Walsh MD.

Cancer Cytopathol. 2014 Apr;122(4):307-12. doi: 10.1002/cncy.21393. Epub 2014 Jan 13.

14.

Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?

Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, Sato Y, Aoyama H, Hayashi T, Kushima R.

Hum Pathol. 2008 May;39(5):666-71. doi: 10.1016/j.humpath.2007.09.009. Epub 2008 Mar 12.

PMID:
18339419
15.

Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients.

Matsuoka K, Ohsumi S, Takashima S, Saeki T, Aogi K, Mandai K.

Breast Cancer. 2003;10(4):330-4.

PMID:
14634511
16.

Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens.

Fiel MI, Cernaianu G, Burstein DE, Batheja N.

Acta Cytol. 1996 Jul-Aug;40(4):637-41.

PMID:
8693878
17.
18.

The diagnostic role of claudins in serous effusions.

Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IeM, Davidson B.

Am J Clin Pathol. 2007 Jun;127(6):928-37.

PMID:
17509990
20.

Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal.

Longatto Filho A, Alves VA, Kanamura CT, Nonogaki S, Bortolan J, Lombardo V, Bisi H.

Acta Cytol. 2002 Jul-Aug;46(4):651-8.

PMID:
12146025

Supplemental Content

Support Center